Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Product › Details


Products Next higher product group ipilimumab (MDX-010)
Period Status 2011-07-19 sales start
  Annual sales USD 706,000,000 (sales (2012) 2012)
  Document for annual sales AMP Biosimilars AG. (4/2/15). "Corporate Presentation [April 2015]". Hamburg.
Organisation Organisation Bristol-Myers Squibb GmbH & Co. KGaA (BMS)
  Group Bristol-Myers Squibb (BMS) (Group)

Redx Pharma Ltd.. (5/2/13). "Press Release: Redx Pharma and Pharmascience Enter into License Agreement for cFMS Cancer Program". Liverpool & Montreal.

The early stage drug development company Redx Pharma has today reached an agreement with Canadian-based Pharmascience Inc. to licence its promising anti-cancer program which helps the immune system to recognise and fight cancer.

The program is focused on small molecules that inhibit a receptor in the body called CSF-1R or cFMS which plays an important role in the immune response to cancer.

The receptor influences the way that the body's immune system interacts with cancer cells in tumours. It also affects how quickly cancer spreads to other parts of the body, particularly to bones.

The license agreement allows Liverpool-based Redx to pursue research and development and commercialization of the Pharmascience program in oncology. The program is currently at the lead optimization stage.

Pharmascience's novel cFMS inhibitors may help prevent the innate immune system from "tolerating" cancer by keeping macrophages, an important type of immune cell, from converting to their pro-inflammatory, but tumour-tolerant state. By inhibiting this key element of cancer's ability to hide from the immune system, these compounds may help the body's immune system to better recognize and kill cancers.

The compounds may also reduce the ability of metastatic cancer cells from being deposited in the bones of cancer patients. Bone metastases are a serious and painful complication of several major cancers including breast and prostate cancer.

Helping the body's own immune system better recognize and fight cancer is an approach that is attracting significant industry attention following recent validation of this approach by successful therapeutics such as BMS's Yervoy™.

Dr Neil Murray, chief executive of Redx Pharma, said: "We're delighted to have reached this agreement with Pharmascience. Helping the immune system to effectively deal with and target cancer cells is an extremely exciting emerging area of science and the cFMS oncology program we have licensed has demonstrated the ability to inhibit tumour growth in animal models. By in-licensing this program we are able to both enter this important emerging area of cancer research and advance our overall stage of development as a company."

Dr. Mathieu Boudreau, Director of Business Development and Strategic Planning of Pharmascience, commented: "Our discovery research team has identified very promising cFMS inhibitor leads and we strongly believe the Redx research team is well positioned to continue the work we have initiated on this project, while we focus on our BTK inhibitor program and other emerging research programs and progress AEG40826, our IAP inhibitor, into Phase 1b/2 studies. We strongly believe that continued success in our industry will arise through such collaborations and shared efforts."

Financial terms were not disclosed.

Record changed: 2019-01-04


Picture [LSE] – The Business Web Portal 650x65px

More documents for MAb

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top